Effect of pharmacist-led medication review on time to diagnosis among pregnant women
Published
December 16, 2024
Paper ID
PAP-000021
Status
Published
DOI
10.65712/tmj.test000279
Advance Services
Abstract
Background: time to diagnosis remains a leading cause of avoidable harm among pregnant women. Methods: Eligible participants were pregnant women. Results: time to diagnosis occurred in 14% of the intervention group versus 18% of controls. The adjusted odds ratio was 0.48 (95% CI 0.49 to 0.97). Conclusion: Future work should test pharmacist-led medication review in a pragmatic multicentre trial.
Introduction
Guidelines make only a weak recommendation on pharmacist-led medication review. The cost of time to diagnosis to health systems is substantial.
time to diagnosis remains a leading cause of avoidable harm among pregnant women. Guidelines make only a weak recommendation on pharmacist-led medication review.
Practice around pharmacist-led medication review varies widely between centres. Guidelines make only a weak recommendation on pharmacist-led medication review. The cost of time to diagnosis to health systems is substantial.
time to diagnosis remains a leading cause of avoidable harm among pregnant women. Practice around pharmacist-led medication review varies widely between centres. Earlier studies of pharmacist-led medication review were small or single-centre.
Discussion
Implementation will depend on staffing, cost and local protocols. Strengths include the sample size and blinded outcome assessment.
These findings suggest that pharmacist-led medication review is associated with better time to diagnosis in pregnant women. Future work should test pharmacist-led medication review in a pragmatic multicentre trial.
Implementation will depend on staffing, cost and local protocols. Residual confounding cannot be excluded.
Conclusions
Pharmacist-led medication review should be considered for pregnant women to improve time to diagnosis.
References
1. Nasser L, Patel Z, et al. Early enteral nutrition and surgical site infection. Eur Heart J. 2025;371(3):216-1070.
2. Farouk E, Lindqvist J, et al. Point-of-care ultrasound and 30-day readmission. Crit Care Med. 2023;256(12):643-1160.
3. Tanaka T, Haddad A, et al. Home-based cardiac rehabilitation and 30-day readmission. BMC Med. 2008;78(6):437-1073.
4. Zhang O, Kowalski N, et al. A sepsis alert system and emergency department revisits. Crit Care Med. 2018;369(2):832-990.
5. Ahmed J, Rahman A, et al. Vitamin D supplementation and glycaemic control. Pediatrics. 2014;20(7):141-1163.
6. Haddad W, Silva J, et al. A sepsis alert system and post-operative delirium. Diabetes Care. 2016;368(11):43-1528.
7. Ahmed N, Zhang M, et al. Telemedicine follow-up and glycaemic control. Lancet. 2019;298(4):865-1740.
Appendices
The statistical analysis plan is in the online supplement.
Materials and Methods
Analyses were adjusted for age, sex and baseline severity.
We conducted a pilot feasibility study across 2 centres between 2015 and 2024. Analyses were adjusted for age, sex and baseline severity. Missing data were handled with multiple imputation.
Eligible participants were pregnant women. Missing data were handled with multiple imputation. We conducted a pilot feasibility study across 10 centres between 2019 and 2022. The primary outcome was time to diagnosis, assessed blind to allocation.
Eligible participants were pregnant women. Missing data were handled with multiple imputation. Analyses were adjusted for age, sex and baseline severity.
Results
2251 participants were included (median age 56 years). 1398 participants were included (median age 72 years).
The adjusted odds ratio was 0.51 (95% CI 0.49 to 0.62). Serious adverse events were rare and similar between groups. time to diagnosis occurred in 6% of the intervention group versus 20% of controls.
The adjusted odds ratio was 0.47 (95% CI 0.49 to 0.95). 4055 participants were included (median age 74 years). time to diagnosis occurred in 16% of the intervention group versus 32% of controls.
| Group | n | Events | Rate % | OR | 95% CI |
|---|---|---|---|---|---|
| Female | 408 | 62 | 5.3 | 0.40 | 0.45–1.37 |
| Intervention | 139 | 62 | 24.3 | 0.81 | 0.22–1.20 |
| Control | 306 | 101 | 30.7 | 0.48 | 0.52–1.0 |
| Age < 65 | 514 | 96 | 13.5 | 0.78 | 0.58–1.12 |
| Male | 305 | 32 | 30.6 | 0.49 | 0.59–1.16 |
| Intervention | 349 | 51 | 29.3 | 0.97 | 0.45–1.21 |
Values are n (%) unless stated otherwise.

Shown for pregnant women; error bars are 95% confidence intervals.
Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.84 (95% CI 0.20 to 0.69). time to diagnosis occurred in 13% of the intervention group versus 30% of controls. Serious adverse events were rare and similar between groups.
3852 participants were included (median age 34 years). 1752 participants were included (median age 78 years). Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups.